Jefferies Downgrades Immunogen Inc. (IMGN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Jefferies Downgrades Immunogen Inc. (IMGN) to Hold
December 22, 2014 7:50 AM EST
Cantor Fitzgerald analyst Mara Goldstein reiterated a Hold rating and lowered her price target on Immunogen Inc. (NASDAQ: IMGN) price target of $9.00 (from $14.00) on disappointing MARIANNE news.
Goldstein said Friday's 40% sell-off have been an overreaction but they remain on the sidelines. "The... More
December 19, 2014 1:36 PM EST
Leerink Swann downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $10.85 yesterday.
...
More
December 19, 2014 9:32 AM EST
Credit Suisse analyst Jason Kantor cut estimates and his price target on Neutral-rated Immunogen Inc. (NASDAQ: IMGN) to $10.00 (from $14.00) following disappoint MARIANNE data.
Kantor said investors largely assumed the data would be positive and Kadcyla would be a multi-billion dollar drug. The news... More
December 19, 2014 8:01 AM EST
ImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche (OTC: RHHBY) has announced top-line results of its Phase III MARIANNE study.
The study evaluated three HER2-targeted regimens Kadcyla® (ado-trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy in people with previously... More
